Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
6 June 2019

Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients

Authors: Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham [email protected], and Brahim BookhartAuthor Info & Affiliations
Volume 8, Number 11
https://doi.org/10.2217/cer-2019-0002
PDFFormats

Abstract

Aim: Real-world effectiveness of canagliflozin 300 mg versus glucagon-like peptide-1 receptor agonists (GLP1RAs) was examined in patients with Type II diabetes. Patients & methods: Patients were selected from the Optum integrated database of administrative claims and electronic health record data (1 January 2013 to 31 March 2015). Results: Patients were less likely to discontinue (p < 0.0001) or switch (p = 0.0048), more likely to add-on treatment (p = 0.0314), and achieve HbA1c <8.0% (p = 0.0364) or weight loss ≥5% (p < 0.0001) with canagliflozin versus GLP1RAs over 9 months. Mean HbA1c was similar at 3-month intervals over 9 months with canagliflozin and GLP1RAs. Conclusion: Patients were less likely to discontinue or switch with canagliflozin than GLP1RA, and were more likely to add-on. Canagliflozin patients were more likely to achieve HbA1c <8.0% and weight loss ≥5% than GLP1RA patients.

Supplementary Material

File (supplementary_materials.docx)

References

1.
International Diabetes Federation. IDF Diabetes Atlas (8th Edition). International Diabetes Federation, Brussels, Belgium (2017).
Google Scholar
2.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin. Diabetes 26(2), 77–82 (2008).
Google Scholar
3.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258), 405–412 (2000).
PubMed
Google Scholar
4.
American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care 41(Suppl. 1), S1–S159 (2018).
PubMed
Google Scholar
5.
Garber AJ, Abrahamson MJ, Barzilay JI et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 diabetes management algorithm – 2018 executive summary. Endocr. Pract. 24(1), 91–120 (2018).
PubMed
Google Scholar
6.
Fallon Health. 2018 Healthcare Effectiveness Data and Information Set (HEDIS®) measures (2018). www.fchp.org/providers/resources/hedis-measures.aspx
Google Scholar
7.
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N. Engl. J. Med. 368(17), 1613–1624 (2013).
PubMed
Google Scholar
8.
Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 8(4), 863–873 (2017).
PubMed
Google Scholar
9.
Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 27(12), 2800–2805 (2004).
PubMed
Google Scholar
10.
Nagrebetsky A, Griffin S, Kinmonth AL, Sutton S, Craven A, Farmer A. Predictors of suboptimal glycaemic control in Type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. Diabetes Res. Clin. Pract. 96(2), 119–128 (2012).
PubMed
Google Scholar
11.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10), 752–772 (2016).
PubMed
Google Scholar
12.
Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24(1), 15–30 (2016).
PubMed
Google Scholar
13.
Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Ann. Rev. Med. 66, 255–270 (2015).
PubMed
Google Scholar
14.
Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of Type 2 diabetes. Ann. Pediatr. Endocrinol. Metab. 22(1), 15–26 (2017).
PubMed
Google Scholar
15.
Mearns ES, Sobieraj DM, White CM et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with Type 2 diabetes: a network meta-analysis. PLoS ONE 10(4), e0125879 (2015).
PubMed
Google Scholar
16.
Taieb V, Pacou M, Schroeder M, Nielsen AT, Schubert A, Neslusan C. A network meta-analysis (NMA) to assess the longer-term relative efficacy of canagliflozin in patients with Type 2 diabetes inadequately controlled on metformin. Value Health 18(7), A598 (2015).
Google Scholar
17.
Taieb V, Pacou M, Schroeder M, Nielsen AT, Neslusan C, Schubert A. Bayesian network meta-analysis (NMA) to assess the relative efficacy of canagliflozin in patients with Type 2 diabetes mellitus (T2DM) inadequately controlled with insulin. Value Health 18(7), A598 (2015).
Google Scholar
18.
Van Sanden S, Diels J, Guillon P, Nielsen AT. Bayesian network meta-analysis to assess relative efficacy of canagliflozin versus glucagon-like peptide-1 receptor agonists in dual and triple therapy in patients with Type 2 diabetes mellitus. Value Health 18(3), A54 (2015).
Google Scholar
19.
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes. Metab. 18(8), 783–794 (2016).
PubMed
Google Scholar
20.
INVOKANA® (canagliflozin) tablets, for oral use [package insert]. Janssen Pharmaceuticals, NJ, USA (2018).
Google Scholar
21.
Buysman EK, Chow W, Henk HJ, Rupnow MF. Characteristics and outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr. Disord. 15(1), 67 (2015).
PubMed
Google Scholar
22.
Optum. Real world health care experiences form over 150 million unique individuals since 1993 (2015). www.optum.com/content/dam/optum/resources/productSheets/5302_Data_Assets_Chart_Sheet_ISPOR.pdf
Google Scholar
23.
Optum. Optum integrated data: bring precision to your investment decisions (2014). www.optum.com/content/dam/optum3/optum/en/resources/fact-sheets/Integrated-Data-product-sheet.pdf
Google Scholar
24.
Wysham CH, Lefebvre P, Pilon D et al. Quality measure and weight loss assessment in patients with Type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. BMC Endocr. Disord. 17(1), 32 (2017).
PubMed
Google Scholar
25.
Wysham CH, Pilon D, Ingham M et al. Quality goal attainment and maintenance in patients with Type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Curr. Med. Res. Opin. 34(6), 1125–1133 (2018).
PubMed
Google Scholar
26.
Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with Type 2 diabetes in the United States. J. Med. Econ. 19(12), 1175–1186 (2016).
PubMed
Google Scholar
27.
Cai J, Divino V, Burudpakdee C. Adherence and persistence in patients with Type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, DPP-4 s, or GLP-1 s in the United States. Curr. Med. Res. Opin. 33(7), 1317–1328 (2017).
PubMed
Google Scholar
28.
Lefebvre P, Pilon D, Ingham M et al. Real-world persistence and HbA1c goal attainment in patients with Type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist. Poster presented at: American Association of Clinical Endocrinologists 26th Annual Scientific & Clinical Congress. TX, USA, 3–7 May 2017.
Google Scholar
29.
Wysham C, Pilon D, Ingham M et al. Glycemic control and treatment costs in patients with Type 2 diabetes mellitus initiated on canagliflozin 300 mg or a glucagon-like peptide-1 receptor agonist in a real-world setting. Poster presented at: 77th Scientific Sessions of the American Diabetes Association (ADA). CA, USA, 9–13 June 2017.
Google Scholar
30.
Wysham C, Pilon D, Ingham M et al. Real-world HbA1c levels in the context of persistence, treatment progression, and durability of HbA1c control in patients with Type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist. Poster presented at: 26th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE). TX, USA, 3–7 May 2017.
Google Scholar
31.
Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes. Metab. 9(6), 799–812 (2007).
PubMed
Google Scholar
32.
Feldstein AC, Nichols GA, Smith DH et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 31(10), 1960–1965 (2008).
PubMed
Google Scholar
33.
Wing RR, Lang W, Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with Type 2 diabetes. Diabetes Care 34(7), 1481–1486 (2011).
PubMed
Google Scholar
34.
Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with Type 2 diabetes. Postgrad. Med. 126(3), 7–15 (2014).
PubMed
Google Scholar
35.
Traina SB, Slee A, Woo S, Canovatchel W. The importance of weight change experiences for performance of diabetes self-care: a patient-centered approach to evaluating clinical outcomes in Type 2 diabetes. Diabetes Ther. 6(4), 611–625 (2015).
PubMed
Google Scholar
36.
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 38(6), 1228–1234 (2009).
Google Scholar
|